Expansion Therapeutics, Inc.
10996 Torreyana Road
About Expansion Therapeutics, Inc.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Based on exclusive worldwide rights to groundbreaking research from the laboratory of Matthew D. Disney, Ph.D., at The Scripps Research Institute, Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule binders of RNA. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of disease indications. The company’s initial development focus is on therapies for patients with expansion repeat diseases who currently have limited and unsatisfactory treatment options. Expansion is based in San Diego, California and Jupiter, Florida.
Co-Founder, President and CEO: Kevin M. Forrest, Ph.D.
Scientific Founder: Matthew D. Disney, Ph.D.
Scientific Advisor: Eric Wang, Ph.D.
Acting CMO: Brian Daniels, M.D.
Acting VP R&D Operations: Greg Korbel, Ph.D., M.B.A.
VP Chemistry: Tim Blizzard, Ph.D.
Head of Intellectual Property: John W. Wallen III, Ph.D., J.D.
Please click here for Expansion Therapeutics' pipeline.
3 articles with Expansion Therapeutics, Inc.
Expansion Therapeutics Expands Leadership Team with Two Key Appointments; Names World-Renowned Scientist Lynne E. Maquat, Ph.D., to its Scientific Advisory Board
Additions strengthen management team and position company to advance portfolio of medicines targeting RNA-mediated diseases into the clinic
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
The round was co-led by 5AM Ventures, Kleiner Perkins, Novartis Venture Fund, and Sanofi Ventures.